CV Therapeutics Lets Innovex Do the Legwork--and Pay for Some of It, Too
Contract Sales Organizations have moved past their rent-a-rep past and are now trying to market themselves as full service marketing outsourcers which provide alternatives to co-marketing and outlicensing.. Innovex's recent deal with CV therapeutics, is a case-in-point and may provide a model for biotechs--and even some pharmaceutical companies--to follow in launching products on their own without incurring huge fixed costs.
You may also be interested in...
In the EU, voices calling for a postponement of the IVD Regulation’s 2022 enforcement date are growing louder.
After talking with the FDA, Atox will file an NDA for its necrotizing soft tissue infections therapy despite missing primary endpoints in a pivotal trial, the biotech’s CEO tells Scrip.
Faced with the risk of losing their investment from a possible stock delisting amid prosecutors’ probes into company’s management, SillaJen’s individual minority shareholders are demanding the Korea Exchange resume trading of the biotech’s stock, in a rare united move.